Labiotech.eu

PBC clinical trials: Gannex doses first patient

News and Trends 29 Jun 2022

Deal to advance treatment for autoimmune disease worth $97M

MiroBio, which is developing checkpoint agonists to treat autoimmune disease, has announced the completion of a $97 million deal. The financing is being led by Medicxi with investments from OrbiMed and Monograph Capital and existing investors Oxford Science Enterprises, Samsara Biocapital, SR One and Advent Life Sciences. Funds will primarily be used to advance MiroBio’s […]

June 29, 2022 - 2 minutesmins - By Liza Laws

News and Trends 29 Jun 2022

Watch: Antibody Analytics opens new health sciences center

A new facility dedicated to the advancement of medical research and drug development opened its doors recently in Motherwell, Scotland, as part of a major expansion. Antibody Analytics, one of Scotland’s authorities on immunology, officially cut the ribbon on its new health sciences research center. The unveiling of the new Antibody Analytics Discovery Centre, funded […]

June 29, 2022 - 3 minutesmins - By Jim Cornall

Best in Biotech 29 Jun 2022

7 biotech books to dive into this summer

From the unprecedented speed at which the COVID-19 vaccines were developed to the biggest fraud case in biotech history, to a sci-fi story set in a post-apocalyptic city, here are seven biotech books to check out this summer. With record-breaking heat waves announcing the start of summer, there has never been a better time to […]

June 29, 2022 - 6 minutesmins - By Omnia Ibrahim

precision fermentation cheese croissant wine

In Depth 28 Jun 2022

Protecting our food supply chain with precision fermentation

Many nations are experiencing a food security crisis caused by geopolitical conflicts, extreme weather and supply chain disruption. A wave of precision fermentation companies is working to protect from future food price shocks by producing sustainable protein ingredients from microbes rather than traditional farms. The world is facing a protracted food security crisis with the […]

June 28, 2022 - 8 minutesmins - By Jonathan Smith

News and Trends 28 Jun 2022

Time Partners closes £30M venture fund to back life sciences startups

Time Partners Limited has announced the final closing of its first advised fund, Time Boost Capital I LP, a £30 million ($36.6 million) genomics venture fund to provide match funding to startups graduating from Illumina Accelerator Cambridge, UK. Since opening in July 2020, Illumina Accelerator Cambridge has launched 13 startups focused on harnessing genomics applications […]

June 28, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 28 Jun 2022

Companies unite to bolster diagnostics for cancer and liver disease

Two companies set on making improvements for those with lung cancer, non-alcoholic fatty liver disease and breast cancer have partnered in a bid to bolster noninvasive diagnostics for the conditions. IV Bio-holdings (IVBH), a clinical-stage bio-platform company that conceives, creates and scales first-generation precision health solutions that improves the detection, diagnosis and treatment of disease […]

June 28, 2022 - 2 minutesmins - By Liza Laws

Kintor Pharmaceutical drug gets positive results for breast cancer

News and Trends 28 Jun 2022

Breast cancer drug recommended for approval

A cancer drug from AstraZeneca and Daiichi Sankyo called Enhertu, that reduces the risk of disease progression or even death by 72%, has been recommended for approval in the European Union (EU). The drug containing trastuzumab deruxtecan is specifically engineered for patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer treated with […]

June 28, 2022 - 3 minutesmins - By Liza Laws

News and Trends 28 Jun 2022

MRM Health starts pouchitis clinical trial

MRM Health, a Belgian clinical-stage biopharmaceutical company, has received regulatory approval from the Federal Agency for Medicines and Health Products (FAMHP) in Belgium to start a phase 2 trial with the novel next-generation optimized consortium therapy, MH002, in patients with pouchitis. MH002 is the first consortium therapy in which key disease-driving mechanisms guide therapeutic microbial […]

June 28, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 28 Jun 2022

Trinity, St. James’s and Legend Biotech collaborating on solid tumors

Trinity College and St. James’s Hospital Dublin (SJH) in Ireland have entered into a strategic collaboration with Legend Biotech, a global biotechnology company developing, manufacturing and commercializing novel therapies. Together, they will develop 3D models exploring chimeric antigen receptor T-cell (CAR-T) cell therapies in solid tumors. CAR T-cell therapies are customized for each individual patient. […]

June 28, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 28 Jun 2022

Eiger BioPharmaceuticals presents liver study data

Eiger BioPharmaceuticals, Inc., a commercial-stage biopharma company focused on the development of innovative therapies to treat and cure hepatitis delta virus (HDV) and other serious diseases, has announced data presented at the European Association for the Study of the Liver (EASL) International Liver Congress 2022 that took place June 22-26 in London, U.K. David Cory, […]

June 28, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 28 Jun 2022

Micropep raises €8.75M to develop alternative crop-protection products

French ag-biotech company Micropep, which develops biological micropeptide-based solutions for agriculture, has completed an €8.75 million ($9.3 million) series A1 financing round. Fall Line Capital led the funding, in addition to existing investors, Supernova Invest, Sofinnova Partners, FMC Ventures and IRDI/SORIDEC. Based in Toulouse, Micropep has developed a technological platform that makes it possible to […]

June 28, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 28 Jun 2022

Biogen, citing insurance challenges, shutters one of its Aduhelm studies

A company says it was forced to end an observational trial of Alzheimer’s drug, Aduhelm, after a ruling by US federal insurance program, Medicare. Biogen said a recent coverage decision by Medicare has forced it to abandon the trial of the drug after enrolling just 29 participants. The company said it made the decision to […]

June 28, 2022 - 3 minutesmins - By Liza Laws

Knowledge hub

Categories

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

Approaches

Therapeutic areas

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Deal to advance treatment for autoimmune disease worth $97M

Watch: Antibody Analytics opens new health sciences center

7 biotech books to dive into this summer

Protecting our food supply chain with precision fermentation

Time Partners closes £30M venture fund to back life sciences startups

Companies unite to bolster diagnostics for cancer and liver disease

Breast cancer drug recommended for approval

MRM Health starts pouchitis clinical trial

Trinity, St. James’s and Legend Biotech collaborating on solid tumors

Eiger BioPharmaceuticals presents liver study data

Micropep raises €8.75M to develop alternative crop-protection products

Biogen, citing insurance challenges, shutters one of its Aduhelm studies

Subscribe to our newsletter to get the latest biotech news!

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!